JournalArta
Sunday, November 22, 2026 · JakartaS&P 6,910.39 ▼3.70%USD/IDR 18,158 ▼0.42%
JournalArta
Global Edition
beyond headlines
Advertisement

Anthropic Faces Drugmakers Using AI to Cut Research Time

Major drugmakers say artificial intelligence is shortening early research, with Novo Nordisk reporting fewer design and testing cycles. Anthropic is moving into drug discovery as both a potential partner and competitor, while researchers caution that clinical trials and regulatory reviews may still slow approvals.

By Alistair Sterling
WIB3 min read
Anthropic Faces Drugmakers Using AI to Cut Research Time
Anthropic Faces Drugmakers Using AI to Cut Research Time

Big pharmaceutical companies are watching Anthropic as they use artificial intelligence to shorten drug research. Novo Nordisk says it has cut molecule design and testing cycles from around eight to three, while Novartis reports a shorter path from project start to drug candidate.

The changes affect an early stage of a long process. Nearly nine out of 10 drugs developed using conventional methods fail in clinical trials, while bringing a drug to market can take 10 to 15 years and cost billions, industry group PhRMA says.

GSK, Bristol Myers Squibb, Novartis, Eli Lilly, Novo Nordisk, AstraZeneca and Sanofi say they use AI to design molecules, identify promising candidates and spot safety risks.

Advertisement

Drugmakers report faster research

Novo Nordisk says AI has reduced each cycle of designing, manufacturing and testing molecules from eight weeks to four. Novartis says the average time from project start to a drug candidate has fallen from three years to about 18 months to two years.

Sanofi says an AI-enabled approach saved at least a year in development of its asthma treatment lunsekimig. The approach helped translate early biology into clinical decisions and allowed the company to skip a dose-selection study.

Novartis says AI helped it identify five targets for kidney disease treatments. Bristol Myers says it would not have developed one sickle cell anemia candidate without its AI systems.

Advertisement

Bristol Myers Chief Research Officer Robert Plenge says the company uses AI to refine molecules and simulate results using trial data. Those simulations help it decide which candidates should move forward.

Anthropic enters drug discovery

Anthropic has opened a laboratory, launched research software called Claude Science and is working with partners including Bristol Myers to develop drugs. Novartis CEO Vas Narasimhan has joined its board, while Novo Nordisk uses Anthropic models and Claude Science in research.

Anthropic CEO Dario Amodei said AI could accelerate drug development, though experiments and clinical trials would still take time. He said, “We hope that in the future, fewer families miss a cure by a few years.”

Advertisement

The AI company can be both a collaborator and competitor, according to Aliza Apple, who runs Lilly’s TuneLab. The program gives smaller biotech companies access to some of Lilly’s internal AI models.

GSK Chief Scientific Officer Tony Wood called Anthropic “another competitor.” Bristol Myers and Novo Nordisk see AI companies more as partners.

Novo Nordisk and Sanofi say they do not provide proprietary data to leading AI laboratories to train their models. Anthropic did not respond to a request for comment on its acquisition plans or relationships with drugmakers.

Clinical trials remain a hurdle

Researchers identified 129 AI-enabled drug candidates across 69 companies in March, up from around 117 eight months earlier. Most programs remained in early-stage development.

Advertisement

University of Chicago oncology fellow Dr. Waqas Haque, who helped compile the data, expects more AI-developed drugs to enter research and clinical trials. He cautioned that human trials and regulators could prevent faster approvals.

Sanofi’s global head of computational and AI strategy for research and development, Matt Truppo, expects AI to cut early-discovery timelines by 20% to 25% within two years across more than 100 drug development programs.

Advertisement
What Kind of Holiday Spender Are You? Take the Black Friday QuizTake the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1Magnitude 4.2 Earthquake Wakes Los Angeles Before DawnMagnitude 4.2 Earthquake Wakes Los Angeles Before Dawn
  2. 2Dow Jones Futures Await Reopening After Tech Stocks SlideDow Jones Futures Await Reopening After Tech Stocks Slide
  3. 3Micron Says Memory Has Changed as Shares Fall 13.89%Micron Says Memory Has Changed as Shares Fall 13.89%
  4. 4GTA 6 Draws Review Bombing on MetacriticGTA 6 Draws Review Bombing on Metacritic
  5. 5ORCL Stock Week Ahead: Levels and Scenarios for November 23–27ORCL Stock Week Ahead: Levels and Scenarios for November 23–27
Advertisement
Don't Miss

Latest News

All stories →
  1. Simon Calder Finds £26 Himalayan Helicopter Airport LinkLifestyleSimon Calder Finds £26 Himalayan Helicopter Airport LinkNov 22
  2. S&P 500 Falls as AI Spending Fears Weigh on StocksMarkets · StocksS&P 500 Falls as AI Spending Fears Weigh on StocksNov 22
  3. Benji and Thom Parry Turn Band Years Into Small PondLifestyle · EntertainmentBenji and Thom Parry Turn Band Years Into Small PondNov 22
  4. Miley Cyrus Marries Maxx Morando in Palm Springs CeremonyLifestyle · EntertainmentMiley Cyrus Marries Maxx Morando in Palm Springs CeremonyNov 22
  5. Advertisement
  6. Paul Mescal’s GAA Shorts Meet Dior Runway SpeculationLifestyle · EntertainmentPaul Mescal’s GAA Shorts Meet Dior Runway SpeculationNov 22
  7. Trump Praises China Summit as Leaders Issue Four-Point DeclarationAsia · East AsiaTrump Praises China Summit as Leaders Issue Four-Point DeclarationNov 22
  8. Crypto Sell Setups This Week: JUP, TAO, POL, NEAR Stay Under PressureMarkets · CryptoCrypto Sell Setups This Week: JUP, TAO, POL, NEAR Stay Under PressureNov 22
  9. Regeneron Drug Combination Clears Tumors in Mouse StudyLifestyle · Food & HealthRegeneron Drug Combination Clears Tumors in Mouse StudyNov 22